Drugs / PP1493
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06605651 | Jul 2026 → Mar 2028 expected | periprosthetic joint infection | Phagenix | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05369104 | Jun 2022 → Dec 2023 | periprosthetic joint infection | Phagenix | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PP1493 | “1 mL (PP1493 or PP1815) or 2 mL (PP1493 and PP1815) of suspension of bacteriophages diluted in solution of NaCl 0,9% at the end of DAIR procedure.” NCT05369104 ↗ |
| Modality | Other / unclassified | “suspension of bacteriophages” NCT05369104 ↗ |
| Route | Other | “Single intra-articular injection” NCT05369104 ↗ |